Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-187

firstly that would be very illegal to sabotage a product and no way BP would take such a risk.

furthermore, Avelumab is a sparsely used treatment compared to other drugs available. BP wants good results from this trial, they are probably desperate for Avelumab to be prescribed on a larger scale. They are hoping that Hervaxx will increase effectiveness of Avelumab.

Either way, this is fantastic for Imugene, I have no doubt that other combinations and collaborations are being discussed and at this stage Imugene is saying thanks but no thanks.. for now, but keep your chequebooks open because the best is yet to come.
To me it looks like Imugene is very carefully selecting where and how to allow BP in. This is just the first of some huge opportunities to come.